Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein

Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) dramatically improve progression-free survival compared to cytotoxic agents. It is therefore important to manage patients with ALK-TKIs until drug resistance occurs. Leukocytoclastic vasculitis (LCV) is a rare complication during can...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Okimoto, Tamio, Tsubata, Yukari, Hotta, Takamasa, Hamaguchi, Megumi, Okuno, Takae, Shiratsuki, Yohei, Kodama, Akari, Nakao, Mika, Amano, Yoshihiro, Hamaguchi, Shunichi, Kurimoto, Noriaki, Tobita, Reiko, Isobe, Takeshi
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929456/
https://ncbi.nlm.nih.gov/pubmed/29732013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24765
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares